| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23073 |
| Drug |
Tremelimumab |
| Brand |
Imjudo® |
| Indication |
Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma. |
| Rapid review commissioned |
06/12/2023 |
| Rapid review completed |
11/01/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tremelimumab in combination with durvalumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/02/2024 |
| Pre-submission consultation with Applicant |
26/03/2024 |
| Full submission received from Applicant |
16/07/2024 |
| Preliminary review sent to Applicant |
20/03/2025 |
| NCPE assessment re-commenced |
24/04/2025 |
| Follow-up to preliminary review sent to Applicant |
02/05/2025 |
| NCPE assessment re-commenced |
08/05/2025 |
| Factual accuracy sent to Applicant |
06/06/2025 |
| NCPE assessment re-commenced |
13/06/2025 |
